People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

A new treatment being offered by High Plains Mental Health Center is proving to be life-changing for some people suffering ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...